The quest to comprehend genetic, biological, and symptomatic heterogeneity underlying Alzheimer's disease (AD) requires a deep understanding of mechanisms affecting complex brain systems. Neuroimaging genetics is an emerging field that provides a powerful way to analyze and characterize intermediate biological phenotypes of AD. Here, we describe recent studies showing the differential effect of genetic risk factors for AD on brain functional connectivity in cognitively normal, preclinical, prodromal[ 2 2 4 _ T D $ D I F F ] , and AD dementia individuals. Functional neuroimaging genetics holds particular promise for the characterization of preclinical populations; target populations for disease prevention and modification trials. To this end, we emphasize the need for a paradigm shift towards integrative disease modeling and neuroimaging biomarker-guided precision medicine for AD and other neurodegenerative diseases.
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Pathophysiology, Genetics[ 2 2 5 _ T D $ D I F F ] , and Functional Brain Processing Underlying AD
AD is the most prevalent neurodegenerative disease and commonest type of dementia in people aged >65 years. Despite enormous efforts in global biomedical research and development, the number of affected individuals with AD is dramatically increasing [1] . Therefore, effective prevention and disease-modifying therapies are needed to reduce the future global burden of neurodegenerative diseases and dementia [2, 3] . The genetic, biological, and symptomatic heterogeneity underlying the spectrum of AD clinical phenotypes as well as the complex non-linear progression of the pathophysiological mechanisms are key factors for a decade of failure of AD clinical trials. Once late-stage clinical symptoms appear, the disease shows extensive, advanced, and potentially irreversible neuropathological alterations À such as inflammatory changes, neuritic plaques (also called senile plaques) and neurofibrillary tangles [4] (see Glossary). An emerging exploration of the long and largely uncharted preclinical stages of AD has begun [5] .
To date, the amyloid cascade theory is the prevailing hypothesis on the pathogenesis of AD [6] . It postulates that brain b-amyloid (Ab) accumulation is the primary mechanistic event, or key pathophysiological threshold, impairing synaptic function, later inducing neuronal damage, and finally leading to widespread neurodegeneration and clinical dementia [7] . The detrimental impact of Ab is assumed to emerge at the system level, as brain functional and structural connections are progressively disrupted (for review see [8] ). Moreover, clinical decline Trends Neural rs-fMRI differences are detectable in CN mutation carriers of APOE, PICALM, CLU, and BIN1 genes across the lifespan.
CN individuals carrying risk variants of APOE, PICALM, CLU, or BIN1 and presymptomatic AD individuals showed overlapping rs-fMRI alterations: decreased functional connectivity in the middle and posterior DMN regions, and increased the frontal and lateral DMN areas.
No consistent results were reported in AD dementia, despite findings suggest selective alterations in the DMN and in the executive control network.
Multimodal biomarker data -including distinct combinations of underlying functional neuroimaging genetics patterns -are standardized and integrated according to the integrative disease modeling (IDM) concept. The PM paradigm applies IDM to translate biomarker-indicated, individual-specific, molecular pathophysiological mechanisms into tailored clinical applications.
